Amdokitug Biosimilar Monoclonal Antibody (IL-17A) for Research

Cat No.: GMP-Bios-INN-1074

Anti-IL17A therapeutic antibody (Pre-made Amdokitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Amdokitug (development code SSGJ-608) is a humanized monoclonal antibody targeting interleukin-17A (IL-17A). It is developed by Sunshine Guojian Pharmaceutical (Shanghai) for psoriasis. It is in Phase III clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1074-1mg 1mg 3090
GMP-Bios-INN-1074-10mg 10mg
GMP-Bios-INN-1074-100mg 100mg
GMP-Bios-INN-1074-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Amdokitug biosimilar, Whole mAb, Anti-IL17A Antibody: Anti-IL-17A/IL17A/IL17/Interleukin-17A therapeutic antibody
INN Name Amdokitug
Target IL17A
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC